TY  - GEN
AU  - Bayraktar,Soley
AU  - Royce,Melanie
AU  - Stork-Sloots,Lisette
AU  - de Snoo,Femke
AU  - Glück,Stefan
TI  - Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy
SN  - 1559-131X
PY  - 2015///1117
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Biomarkers, Tumor
KW  - genetics
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Capecitabine
KW  - Deoxycytidine
KW  - analogs & derivatives
KW  - Docetaxel
KW  - Female
KW  - Fluorouracil
KW  - Gene Expression Profiling
KW  - methods
KW  - Humans
KW  - Middle Aged
KW  - Mutation
KW  - Neoadjuvant Therapy
KW  - Polymerase Chain Reaction
KW  - Prospective Studies
KW  - Receptor, ErbB-2
KW  - metabolism
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Retrospective Studies
KW  - Taxoids
KW  - Trastuzumab
KW  - Treatment Outcome
KW  - Tumor Suppressor Protein p53
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s12032-014-0163-9
ER  -